Merck (MRK), ARIAD (ARIA) Issue Statement Following FDA Panel Decision on Ridaforolimus
Go back to Merck (MRK), ARIAD (ARIA) Issue Statement Following FDA Panel Decision on Ridaforolimus| Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) | Delayed: 23.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.99 | 52 Week High | $14.34 | |||
| Open | $3.07 | 52 Week Low | $4.37 | |||
| Day High | $23.99 | P/E | N/A | |||
| Day Low | $23.99 | EPS | $-1.45 | |||
| Volume | 208,921 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 131.07 +0.59 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.48 | 52 Week High | $65.46 | |||
| Open | $131.44 | 52 Week Low | $47.97 | |||
| Day High | $131.71 | P/E | 89.16 | |||
| Day Low | $130.24 | EPS | $1.47 | |||
| Volume | 6,154,306 | |||||
